AmelieLLM Engineering: planning and reasoning for matching patients to clinical trialsExploring TrialMatchLLM as an Autonomous Agent for improving LLM Reliability in ClinicalResearchMar 28Mar 28
AmelieThe Rise of GPT-Generated Scientific Reports: Navigating Trust and EfficiencyWhen the synthesis of medical knowledge condenses from taking weeks to mere minutes with MedGPT360Jul 16, 20232Jul 16, 20232
AmelieinVitae EvidenceChatGPT for unlocking Outcomes from Clinical TrialsThis post was written in February 2023 - it is still relevant for the public free version based on GPT 3.5, however it does not assess…Jul 9, 2023Jul 9, 2023
AmelieStatus and Further focus on Clinical Studies in NorwayIt is now 2 years since the first action plan for clinical trials was launched in Norway. At a breakfast seminar on Thursday 26 January…Jan 27, 2023Jan 27, 2023
AmelieinVitae EvidenceThe EU policy debates that could secure the data ecosystems enabling equitable access to treatment.A lot is happening in the health-related legislation landscape in Europe, which some described as a once-in-a-generation opportunity:Nov 6, 2022Nov 6, 2022
AmelieinVitae EvidenceFrom “Scientists’ Garage” to spin-offOver three years, I have seen our personalised medicine solution develop from resembling a “scientists garage” to the creation of two…Aug 22, 2022Aug 22, 2022
AmelieinVitae Evidence7 ways Digital Health can accelerate access to life-saving medicineWhen medicines are unaffordable, they cannot save lives. We need to use the technology that our times deserve for faster equitable access.May 14, 2022May 14, 2022
AmelieinVitae EvidenceIncreased access to clinical studies: Yes, but not at all costs.More patients will now have the opportunity to participate in clinical studies. How to tackle trusts issues and ethical concerns?May 8, 2022May 8, 2022
AmelieinVitae EvidenceNordics inequity in reimbursement of personalised medicine and how Digital Health can tackle these.Why must Norwegians wait longer than Danes to access new medicines? How Digital Health can support the most optimal outcome-based reimbursmMay 1, 2022May 1, 2022
AmelieinVitae EvidenceBetter use of health data in clinical trials.The political paper “Action Plan for Clinical Studies (2021–2025)” was recently released in Norway by the Ministry of Health and Care…Apr 11, 2022Apr 11, 2022